Monographie - Oxaliplatin

Ultimo aggiornamento :
08/05/2024

Oxaliplatin

Struttura chimica

Nome commerciale

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Axiplatin	Germania
Bendaplatin	Germania
Bioezulen	Brasile
Celdach	Perù
Crisapla	Chile, Ecuador, Venezuela
Crisatinox	Turchia
Dabenzol	Argentina, Ecuador
Dacplat	Argentina
Eloxarin	Ecuador
Eloxatin	Austria, Belgio, Brasile, Chile, Colombia, Egitto, Emirati Arabi Uniti, Gran Bretagna, Iran, Italia, Lussemburgo, Malaysia, Messico, Norvegia, Nuova Zelanda, Perù, Portogallo, Romania, Spagna, Stati Uniti d’America, Svezia, Svizzera, Tailandia, Turchia, Venezuela
Eloxatine	Francia, Marocco, Svizzera
Entia	Colombia, Messico
Euroxaliplatine	Germania
Glenoxal	Perù
Goxyral	Argentina, Ecuador
Kebir	Argentina, Perù
Linoxa	Turchia
Lisix	Chile
Metaplatin	Argentina
Oliptino	Argentina
Onicol	Chile, Perù
Oxalibbs	Brasile
Oxaliplan	Germania
Riboxatin	Germania

Bibliografia : Oxaliplatin

	Tipo	Pubblicazione
1662	Rivista	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1950	Rivista	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
2207	Rivista	André A, Cisternino S, Roy A.L, Chiadmi F, Schlatter J, Agranat P, Fain O, Fontan J.E. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. Am J Health-Syst Pharm 2007 ; 64, 18: 1950-1954.
2239	Rivista	Wang C, Zhang X, Liu HY. Determination of the stability of oxaliplatin for injection by dual wavelength spectrophotometry. Chinese J New Drugs 2005 ; 14, 2: 189-191.
2253	Rivista	Curis E, Provost K, Bouvet D, Nicolis I, Crauste-manciet S, Brossard D, B?nazeth S. Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS. J Synchrotron Rad 2001 ; 8: 716-718.
2258	Laboratorio	Stability of oxaliplatin "Ebewe" lyophilisate after reconstitution. Ebewe Pharma 2007
2259	Laboratorio	Stability of oxaliplatin "Ebewe" lyophilisate infusion solutions. Ebewe Pharma 2007
2321	Rivista	Junker A, Roy S, Desroches M.C, Moussay C, Berhoune M, Bellanger A, Fernandez C,Farinotti R. Stability of Oxaliplatin Solution. Ann Pharmacotherapy 2009 ; 43,2: 390-391.
2791	Rivista	Mehta A.M,.Van den Hoven J.M, Rosing H,.Hillebrand M.J.X, Nuijen B,. Huitema A.D.R, Beijnen J.H,.Verwaal V.J. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm 2015 ; 479 : 23-27.
2883	Rivista	Eiden C, Philibert L, Bekhtari K, Poujol S, Malosse F, Fr?d?ric Pinguet F. Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags. Am J Health-Syst Pharm 2009 ; 66, 21: 1929-1933.
3369	Laboratorio	Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011
3413	Rivista	Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res 2004 ; 21, 5: 891-894.
3602	Laboratorio	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3634	Laboratorio	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3670	Rivista	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3706	Rivista	Escudero-Ortiz V, Duart-Duart M.J, P?rez-Ruixo C, P?rez-Ruixo J.J, Valenzuela B. Estudio de estabilidad de oxaliplatino y doxorrubicina para su administración intraperitoneal con hipertermia. Farm Hosp 2014 ;38, 3:154-161
4004	Rivista	Krämer I, Sarakbi I, Thiesen J, Mainz. Physikalisch-chemische Stabilität von Oxaliplatin-beta-Infusionslösungskonzentrat und Infusionslösungen in 5 % Glucose in Polyolefin-Infusionsbeuteln. Krankenhauspharmazie 2017 ;38,7:334?340.

Mentions Légales